DOM

5-HT_2A Partial Agonism & G_q Signaling

DOM is a ring-substituted amphetamine psychedelic — structurally a phenethylamine carrying 2,5-dimethoxy substitution plus a lipophilic 4-methyl group, mounted on an amphetamine (α-methyl) backbone. Its psychedelic pharmacology is 5-HT_2A receptor agonism — behaviorally a partial agonist that activates G_q/PLC signaling in layer V cortical pyramidal neurons. Unlike cocaine (DAT blockade) or MDMA (SERT substrate efflux), DOM is not a monoamine releaser or reuptake inhibitor at psychedelic doses — the α-methyl group is present, but the 2,5-dimethoxy-4-methyl ring redirects the molecule toward the 5-HT₂ receptor family rather than the transporters.

The receptor-level event is stabilization of the active-state, transducer-coupled conformation of 5-HT_2A, driving G_q → PLCβ → IP₃/DAG and downstream cortical glutamate release. This is the same orthosteric mechanism as LSD and psilocin — DOM simply reaches it from the phenethylamine side of the pharmacophore rather than the ergoline/tryptamine side.

The α-Methyl Trap: Why STP Never Ends

DOM's defining pharmacokinetic feature is duration. The α-methyl substituent that classifies it as an amphetamine rather than a phenethylamine sterically shields the amine from monoamine oxidase — the enzyme that clears simple phenethylamines and tryptamines within minutes. With the primary rapid-clearance route closed, DOM must be eliminated by slower hepatic O-demethylation (CYP2D6) and subsequent conjugation, producing a plateau that commonly runs 14–20 hours and, at high doses, has been described stretching toward a day or more.

Metabolism cascade: With oxidative deamination unavailable, clearance is dominated by O-demethylation of the aromatic methoxy groups followed by O-methylation (COMT) and glucuronide/sulfate conjugation. The parent drug is the pharmacologically active species; the demethylated/conjugated metabolites are the excreted, largely inactive forms.

The clinical consequence of the blocked MAO route is the entire "STP" story. A tryptamine trip is self-limiting because MAO ends it; DOM has no such off-switch built into its side chain. The drug simply has to be metabolized slowly by the liver, which is why the experience outlasts a full night's sleep. Combined with the slow 0.5–1.5 h onset, this pharmacokinetic profile is the root cause of the redosing catastrophe described in the harm-reduction section below.

CYP2D6 poor metabolizers (~7–10% of people of European descent) lack the primary O-demethylation route and would be expected to have even longer, more intense exposure at a given dose — a plausible contributor to the historically erratic dose–response reports for DOM.

The 1967 "STP" Overdose Scare

DOM was synthesized by Alexander Shulgin and briefly investigated (reportedly at Edgewood Arsenal) before appearing on the street. In mid-1967 large, high-milligram "STP" tablets circulated in San Francisco's Haight-Ashbury. Because the tablets were dosed far above DOM's narrow active range and because DOM has an unusually slow onset, multiple emergency-room presentations followed — the incident that fixed DOM in pharmacological history as a cautionary tale.

A further historical wrinkle: some 1967 "STP" casualties were treated with chlorpromazine, a 5-HT_2A/α-adrenergic/anticholinergic antagonist. Rather than cleanly reversing the state, it could deepen hypotension and anticholinergic toxicity over DOM's very long time-course — reinforcing the lesson that ultra-long, high-potency 5-HT_2A agonists are managed with time, calm, and supportive care, not sedative polypharmacy.

Conformational Entropy Collapse at 5-HT_2A

From a FlexAID∆S first-principles view, binding affinity is a free-energy balance, ΔG = ΔH − TΔS, and DOM's potency is best read as a favorable enthalpic anchoring paid for with a modest configurational-entropy penalty. The protonated amine forms the conserved salt bridge to Asp3.32 and the 2,5-dimethoxy oxygens hydrogen-bond into the pocket — strong, directional ΔH terms. The distinguishing 4-methyl group buries into a hydrophobic sub-pocket, a classic hydrophobic-effect contribution that releases ordered water (a solvent-entropy gain, favorable ΔS) while costing little internal flexibility, because DOM is a small, rigid aromatic with only a short rotatable side chain.

The Shannon-entropy framing makes the potency intuitive: DOM has a small conformational ensemble to begin with, so the entropy collapse on locking into the orthosteric pose — the loss of side-chain and pose micro-states (Boltzmann-weighted, hence a reduction in the binding-mode Shannon entropy) — is smaller than for a floppy ligand. A rigid, pre-organized binder pays a lighter −TΔS tax, which is a large part of why single-digit-milligram DOM is active where a conformationally noisier molecule would need far more. The 4-methyl group's hydrophobic burial simultaneously raises the favorable enthalpy and offsets that penalty through desolvation entropy.

Because no DOM co-crystal exists, the structure at right is the closest experimentally-determined proxy: the human 5-HT_2A receptor captured in its G_q-active state with the phenethylamine agonist 25CN-NBOH (PDB 6WHA). It shows the exact orthosteric pocket and active-state transducer coupling DOM is proposed to engage — the receptor scaffold on which a DOM ΔS_conf / ΔS_vib decomposition would be computed.